Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas
Antoîne Italiano, Angela Cioffi, Nicolas Penel et al. · Cancer · 2011
BACKGROUND: Data regarding the role of anthracyclines and taxanes as first-line treatments of metastatic angiosarcoma are limited. METHODS: Records of 117 metastatic angiosarcoma patients who were treated with either doxorubicin or weekly paclitaxel were reviewed. RESULTS: Seventy-five patients (64%) were treated with weekly paclitaxel and 42 (36%) with single-agent doxorubicin. Patients in the weekly paclitaxel group were older and more frequently had angiosarcomas arising from the skin. In the doxorubicin group, 34 patients were evaluable for response: 2 (6%) had complete response, 8 (23.5%) had partial response, 10 (29.5%) had stable disease, and 14 (41%) had progressive disease. In the weekly paclitaxel group, 68 patients were evaluable for response: 9 (13%) had complete response, 27 (40%) had partial response, 20 (29.5%) had stable disease, and 12 (17.5%) had progressive disease. Objective responses to weekly paclitaxel were more frequent in cutaneous angiosarcomas, whereas tumor location did not impact response to doxorubicin. Median progression-free survival (PFS) was 4.9 months (95% confidence interval [95% CI], 3.9-6.0 months). Median overall survival (OS) was 8.5 months (95% CI, 6.4-10.7 months). On multivariate analysis, ECOG performance status (PS) was the sole independent factor associated with PFS and OS. CONCLUSIONS: First-line single-agent doxorubicin and weekly paclitaxel seem to have similar efficacy in metastatic angiosarcomas. Cutaneous angiosarcomas respond favorably to weekly paclitaxel. Best supportive care should be considered in patients with poor PS.
Cited by 160 works. doi:10.1002/cncr.26599
Authors
- Antoîne Italiano
- Angela Cioffi
- Nicolas Penel
- Matteo Giaj Levra
- Corinne Delcambre
- Elsa Kalbacher
- Christine Chevreau
- François Bertucci
- Nicolás Isambert
- Jean‐Yves Blay
- Binh Bui
- Cristina R. Antonescu
- David R. D’Adamo
- Robert G. Maki
- Mary Louise Keohan
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Induction of apoptosis in fibroblasts by c-myc protein
- World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone
- Malignant Vascular Tumors
- Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
- Enzinger and Weiss's Soft Tissue Tumors
- Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
- Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face
- Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
- Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study